Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-189: pembrolizumab plus platinum-pemetrexed versus placebo plus platinum-pemetrexed in first-line metastatic non-squamous non-small cell lung cancer
2015-003694-15Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing Pembrolizumab combination arm with Placebo combination arm (2 arms). Primary endpoint: Progression-free survival. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2015-003694-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003694-15.